Key result
Integrating pulmonary disease into the CKM framework targets shared multisystem pathophysiology and therapeutic convergence.
Why the study?
The cardiovascular–kidney–metabolic syndrome framework overlooks the role of pulmonary disease despite its significant associations and shared mechanisms with cardiometabolic conditions.
Answers are grounded in this paper and cite their sources.
Pulmonary diseases share pathophysiology and risk factors with cardiovascular-kidney-metabolic (CKM) syndrome, warranting an updated 'CKMP' framework for holistic patient care and multidisciplinary research.
The cardiovascular–kidney–metabolic (CKM) syndrome1 has sharpened understanding of the interconnections between obesity, type 2 diabetes (T2D), hypertension, atherosclerotic cardiovascular disease (ASCVD), metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD). By framing these conditions as a multisystem disorder, CKM catalyses holistic risk assessment and treatment. Yet the lungs—central to gas exchange, inflammatory signalling, vascular tone and autonomic regulation—remains overlooked. There are numerous associations between cardio–kidney, adiposity, abnormal glucose and lipid metabolism and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD), obstructive sleep apnoea (OSA) and pulmonary hypertension (PH). Shared mechanisms including inflammation, insulin resistance, endothelial dysfunction and autonomic neuropathy connect these diseases. Pulmonary disorders amplify cardiometabolic risk, accelerate heart and kidney injury and increase multimorbidity (Figure 1).2 In the era of multisystem therapies and shared mechanisms, treating pulmonary disease in isolation is increasingly illogical. We argue pulmonary disorders should be incorporated into a cardio–kidney–metabolic–pulmonary (CKMP) framework. We highlight epidemiologic and mechanistic links, therapeutic convergence, and the emerging adipokine-based model unifying COPD and heart failure with preserved ejection fraction (HFpEF).3
No takes yet. Share an insight, caveat, or question.
Lam et al. (2026) conducted a review in Cardiovascular-kidney-metabolic (CKM) syndrome and pulmonary diseases. Pulmonary disorders should be integrated into a unified cardiovascular-kidney-metabolic-pulmonary framework to address shared pathophysiology and multisystem therapeutic convergence.
Synapse has enriched 10 related papers. Consider them for comparative context: